Cyntia Silva Oliveira

Dr. Cyntia Silva Oliveira

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
CPCibele Nicolaski Pedron
Cibele Nicolaski Pedron
Cyntia Silva OliveiraCyntia Silva Oliveira
Cyntia Silva Oliveira
ASAdriana Farias da Silva
Adriana Farias da Silva
GAGislaine Patricia Andrade
Gislaine Patricia Andrade
MPMaria Aparecida da Silva Pinhal
Maria Aparecida da Silva Pinhal
VJVani Xavier Oliveira Jr.
Vani Xavier Oliveira Jr.

19 October 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
CPCibele Nicolaski Pedron
Cibele Nicolaski Pedron
MTMarcelo Der Torossian Torres
Marcelo Der Torossian Torres
Cyntia Silva OliveiraCyntia Silva Oliveira
Cyntia Silva Oliveira
ASAdriana Farias Silva
Adriana Farias Silva
GAGislaine Patricia Andrade
Gislaine Patricia Andrade
VJVani Xavier Oliveira Jr.
Vani Xavier Oliveira Jr.
The physicochemical and structural properties of antimicrobial peptides (AMPs) determine their mechanism of action and biological function. However, the development of AMPs as therapeutic drugs has been traditionally limited by their toxicity for human cells. Tuning the physicochemical properties of such molecules may abolish toxicity and yield synthetic molecules displaying optimal safety profiles and enhanced antimicrobial activity. Here, natural peptides were modified to improve their activity by the hybridization of sequences from two different active peptide sequences. Hybrid AMPs (hAMPs) were generated by combining the amphipathic faces of the highly toxic peptide VmCT1, derived from scorpion venom, with parts of four other naturally occurring peptides having high antimicrobial activity and low toxicity against human cells. This strategy led to the design of seven synthetic bioactive variants, all of which preserved their structure and presented increased antimicrobial activity (3.1–128 μmol L−1). Five of the peptides (three being hAMPs) presented high antiplasmodial at 0.8 μmol L−1, and virtually no undesired toxic effects against red blood cells. In sum, we demonstrate that peptide hybridization is an effective strategy for redirecting biological activity to generate novel bioactive molecules with desired properties.

22 October 2019 in Journal of Peptide Science
Verified
Journal Article
Closed access
PDF file
IAIsabel Cristina Chica Acevedo
Isabel Cristina Chica Acevedo
PJPedro Ismael Silva Jr
Pedro Ismael Silva Jr
FSFernanda Dias Silva
Fernanda Dias Silva
IAIris Araújo
Iris Araújo
FAFlávio Lopes Alves
Flávio Lopes Alves
VJVani Xavier Oliveira Jr.
Vani Xavier Oliveira Jr.

9 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Laertty Garcia de Sousa CabralLaertty Garcia de Sousa Cabral
Laertty Garcia de Sousa Cabral
Cyntia Silva OliveiraCyntia Silva Oliveira
Cyntia Silva Oliveira
KFKatielle Albuquerque Freire
Katielle Albuquerque Freire
MAMonique Gonçalves Alves
Monique Gonçalves Alves
VJVani Xavier Oliveira Jr.
Vani Xavier Oliveira Jr.
DMDurvanei Maria
Durvanei Maria
Breast cancer is the most common cancer in women, the so-called “Triple-Negative Breast Cancer” (TNBC) subtype remaining the most challenging to treat, with low tumor-free survival and poor clinical evolution. Therefore, there is a clear medical need for innovative and more efficient treatment options for TNBC. The aim of the present study was to evaluate the potential therapeutic interest of the association of the tumor-penetrating BR2 peptide with monophosphoester 2-aminoethyl dihydrogen phosphate (2-AEH2P), a monophosphoester involved in cell membrane turnover, in TNBC. For that purpose, viability, migration, proliferative capacity, and gene expression analysis of proteins involved in the control of proliferation and apoptosis were evaluated upon treatment of an array of TNBC cells with the BR2 peptide and 2-AEH2P, either separately or combined. Our data showed that, while possessing limited single-agent activity, the 2-AEH2P+BR2 association promoted significant cytotoxicity in TNBC cells but not in normal cells, with reduced proliferative potential and inhibition of cell migration. Mechanically, the 2-AEH2P+BR2 combination promoted an increase in cells expressing p53 caspase 3 and caspase 8, a reduction in cells expressing tumor progression and metastasis markers such as VEGF and PCNA, as well as a reduction in mitochondrial electrical potential. Our results indicate that the combination of the BR2 peptide with 2-AEH2P+BR2 may represent a promising therapeutic strategy in TNBC with potential use in clinical settings.

4 September 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Cyntia Silva OliveiraCyntia Silva Oliveira
Cyntia Silva Oliveira
DSDirce Sakauchi
Dirce Sakauchi
ÉSÉrica Akemi Kavati Sasaki
Érica Akemi Kavati Sasaki
ACAurora Marques Cianciarullo
Aurora Marques Cianciarullo
Antigenicity and immunogenicity define a potent immunogen in vaccinology. Nowadays, there are simplified platforms to produce nanocarriers for small-peptide antigen delivery, derived from various infectious agents for the treatment of a variety of diseases, based on virus-like particles (VLPs). They have good cell-penetrating properties and protective action for target molecules from degradation. Human papillomavirus (HPV) causes anogenital warts and six types of cancer in infected women, men, or children, posing a challenge to global public health. The HPV capsid is composed of viral type-specific L1 and evolutionarily conserved L2 proteins. Produced in heterologous systems, the L1 protein can self-assemble into VLPs, nanoparticles sized around 50–60 nm, used as prophylactic vaccines. Devoid of the viral genome, they are safe for users, offering no risk of infection because VLPs do not replicate. The immune response induced by HPV VLPs is promoted by conformational viral epitopes, generating effective T- and B-cell responses. Produced in different cell systems, HPV16 L1 VLPs can be obtained on a large scale for use in mass immunization programs, which are well established nowadays. The expression of heterologous proteins was evaluated at various transfection times by transfecting cells with vectors encoding codon-optimized HPV16L1 and HPV16L2 genes. Immunological response induced by chimeric HPV16 L1/L2 VLP was evaluated through preclinical assays by antibody production, suggesting the potential of broad-spectrum protection against HPV as a prophylactic nanovaccine. These platforms can also offer promising therapeutic strategies, covering the various possibilities for complementary studies to develop potential preventive and therapeutic vaccines with broad-spectrum protection, using in silico new epitope selection and innovative nanotechnologies to obtain more effective immunobiologicals in combating HPV-associated cancers, influenza, hepatitis B and C, tuberculosis, human immunodeficiency virus (HIV), and many other illnesses.

8 June 2023 in Toxicon
Verified
Journal Article
Closed access
PJPedro Nonato da Silva Júnior
Pedro Nonato da Silva Júnior
JNJoão Victor Serra Nunes
João Victor Serra Nunes
BDBruna Ribeiro Duque
Bruna Ribeiro Duque
APAna Júlia Batista Pereira
Ana Júlia Batista Pereira
EMEmanuel Paula Magalhães
Emanuel Paula Magalhães
AMAlice Maria Costa Martins
Alice Maria Costa Martins